ArticleOncoTargets and therapy2016

Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial.

Kevin J Harrington et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.